Capnia Stock Price, News & Analysis (NASDAQ:SLNO)

$1.60 -0.23 (-12.57 %)
(As of 11/20/2017 06:58 AM ET)
Previous Close$1.83
Today's Range$1.57 - $1.84
52-Week Range$1.47 - $6.60
Volume65,400 shs
Average Volume24,630 shs
Market Capitalization$16 million
P/E RatioN/A
Dividend YieldN/A
Beta6.29

About Capnia (NASDAQ:SLNO)

Capnia logoSoleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.


Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:SLNO
  • CUSIP: N/A
  • Web: www.soleno.life
Debt:
  • Current Ratio: 3.69%
  • Quick Ratio: 3.69%
Sales & Book Value:
  • Annual Sales: $1.45 million
  • Price / Sales: 11.03
  • Book Value: $1.02 per share
  • Price / Book: 1.57
Profitability:
  • Trailing EPS: ($2.05)
  • Net Income: ($12,060,000.00)
  • Net Margins: -1,389.76%
  • Return on Equity: -54.11%
  • Return on Assets: -46.95%
Misc:
  • Employees: 29
  • Outstanding Shares: 10,000,000
 

Frequently Asked Questions for Capnia (NASDAQ:SLNO)

What is Capnia's stock symbol?

Capnia trades on the NASDAQ under the ticker symbol "SLNO."

When did Capnia's stock split? How did Capnia's stock split work?

Shares of Capnia reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Capnia stock prior to the reverse split would have 20 shares after the split.

How were Capnia's earnings last quarter?

Capnia, Inc. (NASDAQ:SLNO) issued its quarterly earnings data on Friday, August, 11th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.10. Capnia had a negative net margin of 1,389.76% and a negative return on equity of 54.11%. View Capnia's Earnings History.

Where is Capnia's stock going? Where will Capnia's stock price be in 2017?

1 brokers have issued twelve-month price objectives for Capnia's shares. Their predictions range from $25.00 to $25.00. On average, they expect Capnia's share price to reach $25.00 in the next twelve months. View Analyst Ratings for Capnia.

Who are some of Capnia's key competitors?

Who are Capnia's key executives?

Capnia's management team includes the folowing people:

  • Anish Bhatnagar M.D., President, Chief Executive Officer, Interim Principal Financial and Accounting Officer, Director (Age 49)
  • Jonathan R. Wolter, Interim Chief Financial Officer (Age 67)
  • Anthony Wondka, Vice President - Research and Development (Age 55)
  • Ernest B. Mario Ph.D., Chairman of the Board (Age 78)
  • Edgar G. Engleman M.D., Director (Age 71)
  • Mahendra G. Shah Ph.D., Director (Age 71)
  • Stuart Collinson Ph.D., Independent Director (Age 57)
  • Rajen K. Dalal Ph.D., Independent Director (Age 63)
  • Steinar J. Engelsen M.D., Independent Director (Age 67)

How do I buy Capnia stock?

Shares of Capnia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Capnia's stock price today?

One share of Capnia stock can currently be purchased for approximately $1.60.

How big of a company is Capnia?

Capnia has a market capitalization of $16 million and generates $1.45 million in revenue each year. The company earns ($12,060,000.00) in net income (profit) each year or ($2.05) on an earnings per share basis. Capnia employs 29 workers across the globe.

How can I contact Capnia?

Capnia's mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]


MarketBeat Community Rating for Capnia (NASDAQ SLNO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Capnia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Capnia (NASDAQ:SLNO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (1,462.50% upside)

Consensus Price Target History for Capnia (NASDAQ:SLNO)

Price Target History for Capnia (NASDAQ:SLNO)

Analysts' Ratings History for Capnia (NASDAQ:SLNO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Maxim GroupSet Price TargetBuy$25.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Capnia (NASDAQ:SLNO)

Earnings by Quarter for Capnia (NASDAQ:SLNO)

Earnings History by Quarter for Capnia (NASDAQ SLNO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2017Q2 2017($0.40)($0.30)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.35)($0.55)$0.27 millionViewN/AView Earnings Details
3/15/2017Q4 2016($1.15)($0.82)$0.28 millionViewN/AView Earnings Details
8/12/2016Q2($1.00)($1.15)$0.39 millionViewN/AView Earnings Details
5/10/2016Q115($1.35)($1.10)$0.45 millionViewN/AView Earnings Details
3/24/2016Q4($2.35)($1.10)$242.00 millionViewN/AView Earnings Details
8/7/2015Q215($1.10)$1.25$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Capnia (NASDAQ:SLNO)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Capnia (NASDAQ:SLNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Capnia (NASDAQ SLNO)

Insider Ownership Percentage: 69.75%
Insider Trades by Quarter for Capnia (NASDAQ:SLNO)

Insider Trades by Quarter for Capnia (NASDAQ SLNO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016Bhatnagar AnishInsiderBuy10,000$0.96$9,600.00View SEC Filing  
8/18/2016David D O'tooleInsiderBuy2,000$1.01$2,020.00View SEC Filing  
8/18/2016Ernest MarioDirectorBuy25,000$0.99$24,750.00View SEC Filing  
8/17/2016David D O'tooleInsiderBuy10,000$0.92$9,200.00View SEC Filing  
6/8/2016Ernest MarioDirectorBuy50,000$1.24$62,000.00View SEC Filing  
5/23/2016Steinar J EngelsenDirectorBuy58,200$1.31$76,242.00View SEC Filing  
5/20/2016Ernest MarioDirectorBuy48,806$1.18$57,591.08View SEC Filing  
5/13/2016Bhatnagar AnishCEOBuy5,000$1.15$5,750.00View SEC Filing  
5/12/2016David D O'tooleInsiderBuy5,000$1.16$5,800.00View SEC Filing  
11/18/2015Ernest MarioDirectorBuy50,000$1.77$88,500.00View SEC Filing  
11/17/2015David D O'tooleCFOBuy5,000$1.79$8,950.00View SEC Filing  
9/14/2015David D O'tooleCFOBuy7,500$2.38$17,850.00View SEC Filing  
9/14/2015Ernest MarioDirectorBuy15,000$2.28$34,200.00View SEC Filing  
3/13/2015David D O'tooleCFOBuy5,250$6.23$32,707.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Capnia (NASDAQ SLNO)

Source:
DateHeadline
 Cuts Capnia, Inc. (SLNO) Price Target to $8.00 Cuts Capnia, Inc. (SLNO) Price Target to $8.00
www.americanbankingnews.com - November 19 at 4:56 PM
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 9:27 AM
What Is Soleno Therapeutics Inc’s (SLNO) Share Price Doing?What Is Soleno Therapeutics Inc’s (SLNO) Share Price Doing?
finance.yahoo.com - November 15 at 9:27 AM
Maxim Group Lowers Capnia, Inc. (SLNO) Price Target to $8.00Maxim Group Lowers Capnia, Inc. (SLNO) Price Target to $8.00
www.americanbankingnews.com - November 14 at 4:40 PM
Soleno Therapeutics Regains Compliance with NASDAQ Listing RequirementsSoleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
finance.yahoo.com - October 24 at 10:02 AM
Head to Head Contrast: SeaSpine Holdings Corporation (SPNE) and Capnia (SLNO)Head to Head Contrast: SeaSpine Holdings Corporation (SPNE) and Capnia (SLNO)
www.americanbankingnews.com - October 21 at 4:34 PM
Maxim Group Reiterates $25.00 Price Target for Capnia, Inc. (SLNO)Maxim Group Reiterates $25.00 Price Target for Capnia, Inc. (SLNO)
www.americanbankingnews.com - October 13 at 12:32 AM
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi SyndromeSoleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
finance.yahoo.com - October 12 at 9:36 AM
Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi SyndromeSoleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
finance.yahoo.com - October 12 at 9:36 AM
Capnia, Inc. (SLNO) Upgraded by ValuEngine to SellCapnia, Inc. (SLNO) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - October 6 at 10:34 PM
Soleno Therapeutics Announces 1-for-5 Reverse Stock SplitSoleno Therapeutics Announces 1-for-5 Reverse Stock Split
finance.yahoo.com - October 6 at 11:04 AM
Contrasting Invacare Corporation (IVC) and Capnia (SLNO)Contrasting Invacare Corporation (IVC) and Capnia (SLNO)
www.americanbankingnews.com - October 6 at 2:08 AM
Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi SyndromeSoleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
finance.yahoo.com - September 26 at 4:58 PM
Orthofix International N.V. (OFIX) vs. Soleno Therapeutics (SLNO) Head-To-Head AnalysisOrthofix International N.V. (OFIX) vs. Soleno Therapeutics (SLNO) Head-To-Head Analysis
www.americanbankingnews.com - September 20 at 2:08 AM
Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi SyndromeSoleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome
finance.yahoo.com - September 15 at 9:02 AM
Capnia, Inc. (SLNO) Rating Reiterated by Maxim GroupCapnia, Inc. (SLNO) Rating Reiterated by Maxim Group
www.americanbankingnews.com - September 13 at 4:52 PM
Before You Buy Soleno Therapeutics Inc’s (SLNO), You Should Consider ThisBefore You Buy Soleno Therapeutics Inc’s (SLNO), You Should Consider This
finance.yahoo.com - September 13 at 9:12 AM
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi SyndromeSoleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
finance.yahoo.com - September 13 at 9:12 AM
Soleno Therapeutics Announces CFO TransitionSoleno Therapeutics Announces CFO Transition
finance.yahoo.com - September 6 at 8:22 AM
Soleno Therapeutics, Inc. :SLNO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Soleno Therapeutics, Inc. :SLNO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 12:51 PM
Head to Head Survey: Capnia (SLNO) vs. NeuroMetrix (NURO)Head to Head Survey: Capnia (SLNO) vs. NeuroMetrix (NURO)
www.americanbankingnews.com - August 15 at 4:10 AM
Capnia, Inc. (SLNO) PT Set at $5.00 by Maxim GroupCapnia, Inc. (SLNO) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - August 14 at 11:40 AM
Capnia, Inc. (SLNO) Issues  Earnings Results, Beats Estimates By $0.02 EPSCapnia, Inc. (SLNO) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 12 at 10:40 AM
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 12 at 7:52 AM
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
finance.yahoo.com - July 25 at 6:45 AM
Capnia, Inc. (NASDAQ:SLNO) Given a $5.00 Price Target by Maxim Group AnalystsCapnia, Inc. (NASDAQ:SLNO) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - July 9 at 6:02 PM
Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi SyndromeSoleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
finance.yahoo.com - July 5 at 10:43 AM
After-Hours Stock Movers 05/25: (NTNX) (DECK) (EGHT) Higher; (ZOES) (GME) (SPLK) Lower (more...)After-Hours Stock Movers 05/25: (NTNX) (DECK) (EGHT) Higher; (ZOES) (GME) (SPLK) Lower (more...)
www.streetinsider.com - May 26 at 7:08 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Capnia (NASDAQ SLNO) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.